Stay updated with breaking news from Kari Kendra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer research is looking at expanding a treatment used to fight the most dangerous type of skin cancer, to fight other cancers.
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.
<p style="text-align:start">In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab. These and other results of the analyses are presented as a proffered paper (Abstract LBA48) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Monday, October 23, by Sapna P. Patel, MD, chair of the SWOG melanoma committee and ...
In a phase 2 trial, pembrolizumab produced an overall response rate of 89% in patients with unresectable desmoplastic melanoma.
Pembrolizumab led to a dramatic overall response rate among patients with unresectable desmoplastic melanoma.